And once again (twice in two days!), we feature a very cogent update, from our anonymous readers — likely local to the Oss area (I cleaned up the meaning a bit, for the English sensibilities):
. . . .Merck has now given the Advisory Board in Oss the requested data why the deal with Party X was rejected by Merck. . . .
After studying those data, the Advisory board advised to re-open talks with Party X. According to advisers of the Advisory Board (RABO International and Professor Hans Schenk), the deal would benefit Merck instead of costing some estimated $700 million. If Merck chooses not to re-open the talks with Party X, the Advisory Board advises to keep the R&D open,that’s what they, in fact, meant.
The court case of the Works Council against MSD is cancelled. They would have no chance, as they can’t influence decisions made in the USA.
April 2, 2011 7:31 AM. . . .
I agree — this is likely the end.
Very sad — and all this very public fighting (and reputational damage, for New Merck) might have been avoided, with better EU legal counsel, and a more deft hand, in the planning process. Recall that either Schering-Plough’s, or New Merck’s legal team flat out missed the Dutch legal requirement to obtain the consent of the local Dutch Advisory Board, about a year and three quarters ago — as the bust-up began to take shape. Unfortunate, in the extreem as thousands likely permanently lose their livelihoods, here.